SIS
CNSP icon

Sound Income Strategies’s CNS Pharmaceuticals CNSP Stock Holding History

Sound Income Strategies’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16
Closed -$36 – 842
2026
Q1 		$36 Hold
16
– – ﹤0.01% 2544
2025
Q4 		$113 Buy
+16
New +$120 ﹤0.01% 2452

Other funds holding CNSP

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return

Sound Income Strategies's CNSP Position: Q2 2026 in Review

Sound Income Strategies sold out of CNS Pharmaceuticals (CNSP) in Q2 2026, closing a stake of 16 shares — an estimated $36 sold.

Sound Income Strategies first reported a position in CNSP in Q4 2025 and held it in 2 quarters. The position peaked at $113 in Q4 2025. 11 funds tracked by Wall St. Rank hold CNSP as of Q2 2026.

  • Sound Income Strategies reported no remaining CNS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 16 CNS Pharmaceuticals shares in Q2 2026, an estimated $36.
  • Sound Income Strategies first reported a position in CNS Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Sound Income Strategies's CNS Pharmaceuticals position peaked at $113 in Q4 2025.
  • 11 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.